Search the Newsreel

PDSB Maintained by HC Wainwright & Co. -- Price Target Lowered t

PDS Biotechnology reports Q2 2026 net loss $9.8M, cash $5.6M, strategic refocus on PDS0301

PDS Biotechnology reported a net loss of $9.8 million for Q2 2026 and had $5.6 million in cash at quarter-end. The company announced a strategic refocus to prioritize its tumor-targeted IL-12 program, PDS0301, and will discontinue internal investment in PDS0101, seeking external partnerships for …

PDS Biotechnology: Q2 Earnings Snapshot

PDS Biotech Reports Second Quarter 2026 Financial Results

PDS Biotechnology Corporation announced its financial results for the second quarter ended June 30, 2026, reporting a net loss of $9.8 million. The company also provided a clinical and corporate update, highlighting positive clinical data for PDS0301 in metastatic colorectal cancer and announcing a …

PDS Biotechnology Halts PDS0101 Trial, Pivots to PDS0301 in Colorectal Cancer

PDS Biotechnology has announced the halt of its PDS0101 trial and internal investment, including the discontinuation of the Phase 3 VERSATILE-003 trial, to pivot its resources towards PDS0301. PDS0301, a tumor-targeted IL-12 immunocytokine, will now be the company's lead asset with a priority indication …

PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program

PDS Biotechnology Corporation's stock crashed by approximately 67% after the company announced a strategic refocus of its resources towards the PDS0301 program for metastatic colorectal cancer. This shift is based on encouraging clinical data and a belief that PDS0301 offers a more attractive path …

PDS Biotech to report quarterly financial results

PDS Biotech has scheduled the release of its quarterly financial results for the quarter ending June 30, 2026, on August 13, 2026. This announcement was initially published by PDS Biotechnology Corporation via GlobeNewswire. The news brief was created by Public Technologies (PUBT) using generative …

Form 8K PDS Biotechnology Corp For: 11 August By Investing.com

This article announces the filing of a Form 8K by PDS Biotechnology Corp for August 11, as reported by Investing.com. It provides a brief update on company filings without further details on the content of the Form 8K. The article appears to be a …

PDS0301 Data Show 80% 24-Month Survival With Liver Metastases

PDS Biotechnology (Nasdaq: PDSB) announced a strategic refocus, prioritizing its tumor-targeted IL-12 immunocytokine PDS0301 and discontinuing internal investment in the PDS0101 Phase 3 VERSATILE-003 trial, instead seeking strategic partnerships for PDS0101. This decision follows promising Phase 2 data for PDS0301 in metastatic colorectal cancer …

PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates

PDS Biotechnology Corp (PDSB) Stock News Today

PDSB|PDS Biotechnology Corp|Price:0.691|Chg%:-0.002

This article provides a comprehensive stock analysis of PDS Biotechnology Corp (PDSB) by TradingKey. It highlights the company's strong fundamentals and high growth potential, despite a recent weak stock market performance. The analysis also covers its valuation, institutional ownership, analyst ratings, and PDSB's clinical-stage …

PDS Biotechnology Corp SEC Filing (Jul 22, 2026)

This article reports on an SEC filing by PDS Biotechnology Corp (PDSB) regarding the effectiveness of their S-3 shelf registration statement, with an effective date of July 21, 2026. The filing has a neutral impact and sentiment according to AI-generated analysis. The article also …